CA
ANRO icon

Clearstead Advisors’s Alto Neuroscience ANRO Stock Holding History

Clearstead Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$299K Buy
+13,312
New +$247K ﹤0.01% 863
2025
Q3 		– Sell
-178
Closed -$392 – 3272
2025
Q2 		$392 Buy
+178
New +$424 ﹤0.01% 2514

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clearstead Advisors's ANRO Position: Q1 2026 in Review

Clearstead Advisors opened a new position in Alto Neuroscience (ANRO) in Q1 2026: 13,312 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #863 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ANRO as recently as Q2 2025.

Clearstead Advisors first reported a position in ANRO in Q2 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Clearstead Advisors held 13,312 shares of Alto Neuroscience worth $299K as of Q1 2026.
  • Alto Neuroscience was a new Clearstead Advisors position in Q1 2026.
  • Alto Neuroscience made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #863 holding.
  • Clearstead Advisors first reported a position in Alto Neuroscience in Q2 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.